A major requirement for an effective human immunodeficiency virus (HIV) vaccine is the induction of potent, broad, and durable anti-HIV CD8 ϩ T-cell immunity (11, 21, 28) . Only a few vaccine modalities that safely and effectively induce CD8 ϩ T-cell responses in humans have emerged, and a substantial diversity of approaches are currently being tested in preclinical models (9, 21, 28) . Replicon-based vaccine vectors derived from positive-strand RNA viruses have recently emerged as potentially valuable systems for the development of vaccines (17) . Alphavirus-based replicon vaccines have been shown to be capable of inducing potent antibody and CD8 ϩ T-cell responses in mice and monkeys (22, 34) and have been applied to the design of HIV type 1 (HIV-1) vaccines (7, 39, 42) .
Replicon vectors based on the flavivirus Kunjin (KUN) have recently been developed in our laboratories (18, 19, 40, 41) and show considerable potential for use as vaccine vectors for induction of protective CD8 ϩ T-cell responses (3) . KUN replicon vectors have several potentially valuable characteristics for vaccine design. KUN replicons do not induce cytopathic effects, which allows immunogens to be expressed for extended periods both in vitro and in vivo (19, 40, 41) , thus potentially generating long-lived immunity. Also, flaviviruses are not known to recombine in nature, thus precluding generation of potentially harmful recombinant viruses in KUN replicon-immunized individuals infected with other flaviviruses. Furthermore, the enzootic host of KUN virus appears to be mainly birds, with infections in humans nearly always asymptomatic. There is no preexisting immunity to KUN virus in the majority of the world's populations, except in northern parts of Australia and neighboring islands where KUN virus is endemic. KUN replicon-based vaccines can be delivered in the following two ways: (i) plasmid DNA carrying replicon cDNA, which in turn produces functional replicon RNA in vivo from the cytomegalovirus (CMV) promoter by cellular RNA polymerase II; or (ii) replicon RNA, which is transcribed in vitro and delivered either as naked RNA or packaged into virus-like particles (VLPs) before delivery by infection with these VLPs. KUN replicons are unable to generate infectious virus in vivo, and the design of the heterologous packaging system for production of KUN VLPs also precludes the generation of any infectious recombinant viruses during VLP preparation (18, 40) .
HIV particle assembly and budding are directed by the pr55 gag polyprotein, which is the precursor for the internal structural proteins (matrix, capsid, nucleocapsid, and p6) of the mature virion (6) . HIV Gag proteins are relatively conserved and the target of cross clade immunity (8, 26) . Both CD4 and CD8 ϩ T-cell immunity directed against Gag proteins are believed to be important for protection (10, 15) . Although not believed to mediate protection, anti-Gag antibodies are raised in HIV-infected individuals and by experimental vaccines containing Gag, where the antibody responses may be viewed as one measure of vaccine performance (30) . Here we show that immunization with KUN replicons expressing the complete HIV-1 gag gene induced potent Gag-specific CD8
T-cell and antibody responses and protected mice from challenge with recombinant vaccinia virus expressing the gag gene.
MATERIALS AND METHODS
Plasmids. The RNA-based and DNA-based KUN replicon vectors C20UbHDVrep and pKUNrep1, respectively (41), were used for construction of plasmids containing the HIV-1 gag gene. Essentially, the complete HIV-1 gag gene was amplified by PCR from the pBRDH2-neo plasmid (an HIV-1 SF2/BH10 construct) (14) with primers gagBssHII-F (5Ј-ACCATGGGCGCGAGCATCG GTATTA-3Ј) and gagBssHII-R (5Ј-CTAAAGCGCGCCTTGTGACGAGGGG TC-3Ј). The PCR product was then digested with BssHII and inserted into the AscI sites of the two KUN vectors to produce plasmids KUNgagRNA and KUNgagDNA, respectively (Fig. 1) .
DNA and RNA transfections and immunofluorescence. For DNA transfection, BHK21 cells in 60-mm-diameter dishes or on glass coverslips were transfected with 2 or 0.4 g of plasmid DNA, respectively, using Lipofectamine Plus transfection reagent (Life Technologies, Melbourne, Australia), as described by the manufacturer. RNA was transcribed in vitro from the XhoI-linearized KUNgagRNA plasmid DNA using SP6 RNA polymerase and electroporated into BHK21 cells as described previously (19) . Coverslips with transfected cells were fixed in 4% paraformaldehyde 28 to 48 h posttransfection and assayed for expression of KUN NS3 or E protein by indirect immunofluorescence (IIF) with anti-NS3 or anti-E antibodies, respectively, as described previously (43).
Radioimmunoprecipitation assay (RIPA). To metabolically label proteins, BHK21 cells electroporated with KUNgag RNA were seeded into a six-well plate, and at 32 h postelectroporation, the cells were radiolabeled for 4 h with ϳ100 Ci of [
35 S]methionine/cysteine in the presence of actinomycin D (Sigma, Castle Hill, Australia). Tissue culture fluid was collected, and the cells were lysed in lysis buffer (phosphate-buffered saline [PBS] containing 0.5% Nonidet P-40). Samples were incubated with anti-pr55 gag antibody (diluted 1:50) overnight at 4°C and then incubated for 1 h with 30 l of 10% protein A-Sepharose beads at 4°C. Pelleted Sepharose beads were washed three times with PBS, resuspended in gel loading buffer, boiled for 5 min, and separated on a sodium dodecyl sulfate-10% polyacrylamide gel.
Electron microscopy (EM). BHK21 cells electroporated with KUNgag RNA or KUN vector RNA were seeded into a 60-mm-diameter dish, and the cells were then harvested at 24 and 48 h after electroporation. The cells were collected in PBS and fixed with 3% glutaraldehyde in 0.1 M sodium phosphate buffer, pH 7.4. The samples were treated with 1% osmium tetroxide, dehydrated with acetone, and embedded in Epon 612 resin as previously described (23) . Sections collected on grids were stained with uranyl acetate and lead citrate. All specimens were examined on a JEOL 1010 transmission electron microscope at 80 kV.
Preparation of VLPs. VLPs were prepared essentially as described previously except that 3 ϫ 10 6 BHK21 cells were electroporated with ϳ30 g of in vitrotranscribed KUNgag RNA. At 32 h postelectroporation, the cells were trypsinized, subjected to a second electroporation using in vitro-transcribed noncytopathic Semliki Forest virus (SFV) replicon RNA containing the Leu713-to-Pro codon substitution in the SFV nsP2 gene and encoding KUN structural proteins (derivative of SFV-MEC105) (18) (details will be described elsewhere) and incubated for 48 to 60 h before harvesting secreted VLPs. The titer of HIV Gag protein determination. BHK cells (1.25 ϫ 10 5 of 2 ϫ 10 6 ) electroporated with 5 to 10 g of KUNgag RNA were seeded into each well of a 24-well plate. Culture fluid and cell lysate samples were harvested at various time intervals. The total volume of culture fluid (500 l) was clarified and stored at 4°C. For cell lysate, the cells were washed twice with PBS and lysed in 500 l of PBS containing 0.5% Nonidet P-40 for 5 min at room temperature. Samples were then vortexed, clarified, and stored at Ϫ70°C. The level of pr55 gag protein present in the sample was then quantified by using an indirect CAp24 enzyme-linked immunosorbent assay (ELISA) kit (Perkin-Elmer Life Sciences, Boston, Mass.). The assay was performed as recommended by the manufacturer. The total amount of cell-associated and secreted pr55 gag protein produced per 10 6 initially transfected cells was calculated by multiplying the amount of protein detected in the total volume of samples obtained from 1.25 ϫ 10 5 of initially transfected cells by a factor of 8.
Detection of antibodies to HIV-1 Gag protein by indirect ELISA. Each well of the 96-well plates was coated with 1 g of recombinant pr55
gag protein (expressed as His-tagged protein in Escherichia coli and purified using a Ni-agarose column) overnight at 4°C in antigen coating buffer (15 mM Na 2 CO 3 , 35 mM NaHCO 3 [pH 9.6]). The wells were then blocked by incubation with 50-l portions of blocking buffer (PBS containing 0.25% gelatin and 0.1% Tween 20) for 1 h at 37°C and washed three times with wash buffer (PBS containing 0.05% Tween 20). Serum samples from immunized mice, diluted in blocking buffer, were placed in the wells and incubated for 1 to 2 h at room temperature, and the wells were washed three times. The secondary antibody, horseradish peroxidaseconjugated goat anti-mouse immunoglobulin G diluted 1:2,000 in blocking buffer, was placed in the wells and incubated for 30 min at room temperature. After the wells were washed three times, bound conjugate was developed by incubation with 50 l of K-blue tetramethylbenzidine substrate (Graphic Scientific, Brisbane, Australia) for 10 min at room temperature in the dark or until the color developed. The reaction was then stopped by the addition of 50 l of 2 M H 2 SO 4 , and the absorbance readings (optical density at 450 nm) were determined using an ELISA plate reader. Constructs also contain either an SP6 or CMV promoter upstream of the KUN 5Ј UTR for in vitro or in vivo RNA transcription, respectively. The antigenomic sequence of the hepatitis delta virus ribozyme (HDVr) and the polyadenylation signal from simian virus 40 (pA) have been inserted downstream of the 3Ј UTR to ensure production of KUN replicon RNA molecules with precise 3Ј termini for efficient initiation of replication. Ubiquitin is the mouse ubiquitin gene, and FMDV2A is autoprotease 2A of the foot-and-mouse disease virus.
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the number of NS3-positive Vero cells detected by IIF analysis after infection with serial 10-fold dilutions of the neutralization reaction mixtures. ELISPOT and chromium release assays. Epitope-specific CD8 ϩ T cells secreting gamma interferon (IFN-␥) were enumerated by an enzyme-linked immunospot (ELISPOT) assay using peptide epitopes (Mimotopes, Clayton, Australia) as described previously (20) . The statistical significance of the different values found for the groups was determined using an unpaired Student's t test. 51 Chromium ( 51 Cr) release assays were performed using splenocytes from mice sacrificed 2 to 3 weeks postimmunization, and splenocytes were restimulated in vitro for 6 days with irradiated lipopolysaccharide blasts (responder/stimulator ratio of 20:1) sensitized with the AMQMLKETI peptide (25 g/ml for 1 h in 200 l of medium at 37°C, followed by two washes). The resulting effector populations were split, and equal numbers were used in duplicate experiments against peptide-sensitized and unsensitized 51 Cr-labeled P815 target cells at the indicated effector/target ratios.
Vaccinia virus protection assay. Immunized and control groups of 6-to 8-week-old female BALB/c mice (Animal Resource Center, Perth, Australia) were challenged with recombinant vaccinia virus (TK Ϫ ) carrying the HIV-1 gag gene (rVVgag) (29) or with the control rVV encoding the murine polyepitope (rVVcont) (17) . At day 4 postinfection, both ovaries were removed, washed, and homogenized in 1 ml of PBS using aluminum mesh. The ovary vaccinia virus titers were then determined by plaque assay on confluent CV1 cells (3) . The significance of the differences between the virus titers in the experimental and control groups was calculated using a nonparametric unpaired t test. gag antibodies showed that ϳ40% of cells were strongly positive for both proteins 40 h after transfection with DNA-based replicons (data not shown). In vitro-transcribed KUNgag RNA was transfected into BHK21 cells by electroporation and examined for KUN NS3 expression by IIF analysis with anti-NS3 antibodies and for HIV-1 gag expression and secretion by RIPA with anti-pr55 gag antibody. IIF analysis of RNA-electroporated cells demonstrated significantly greater transfection efficiency compared to cells transfected with the corresponding DNA-based replicon vector, i.e., 85 and 40%, respectively (data not shown). RIPA with antipr55 gag antibody showed efficient Gag expression in KUNgag RNA-electroporated cells and its secretion into the culture fluid ( Fig. 2A) . A decrease in the amount of Gag protein in cells from 0.5 h to 4 h of the chase period ( Fig. 2A , cell lysate lanes), correlated with the appearance of secreted Gag in the culture fluid 4 h after chase labeling (Fig. 2A, lane 2) . The amount of Gag protein present in cells and in the culture fluid was quantitated using an indirect ELISA (Fig. 2B ) with antiCAp24 antibody-coated microtiter plates (Perkin-Elmer Life Sciences). Comparison with a purified p24 protein of known concentration showed that the total amount of Gag protein produced from 10 6 of initially transfected BHK cells 60 h after electroporation of KUNgag RNA was equivalent to 632 ng of CAp24 protein, with 410 ng detected in the cell lysates and 222 ng detected in the culture fluid.
RESULTS

Expression and secretion of gag particles in cells transfected
To examine whether Gag protein was assembled into secreted particles, we performed EM analysis of transfected cells. Characteristic 100-to 120-nm-diameter particles were present in cells transfected with KUNgag RNA (Fig. 3A) but not in cells transfected with the KUN vector replicon RNA (Fig. 3B) . In addition, the assembled gag particles were observed to bud from the plasma membrane (Fig. 3C ) and were released into the extracellular medium (Fig. 3D) . Taken together, the results of IIF, RIPA, ELISA, and EM analyses demonstrate efficient expression of secreted gag particles in cells transfected with KUN replicon vectors carrying the HIV-1 gag gene.
Induction of HIV-1 Gag-specific antibody responses. Sera from mice immunized twice with KUNgag VLPs (10 6 IU per mouse) or once with rVVgag (2 ϫ 10 7 PFU per mouse) were examined for the presence of antibodies to Gag. The antibody responses were similar after immunization with KUNgag VLPs and rVVgag (Fig. 4) .
Absence of neutralizing antibody response to the KUN envelope protein after VLP immunizations. Effective booster immunization using a second inoculation with the same virus vector-based vaccine usually demands that the primary immunizations did not lead to induction of neutralizing antibodies (36) . To determine whether there was any significant neutralizing antibody response to the KUN envelope VLP protein after two immunizations with KUNgag VLPs, a VLP infectivity neutralization assay was performed. In the absence of neutralizing antibodies, VLPs incubated with sera from naive mice showed VLP titers of 2.1 ϫ 10 6 Ϯ 3.8 ϫ 10 5 IU/ml. As expected, in the presence of a neutralizing antienvelope monoclonal antibody, the VLP's infectivity was completely neutralized (data not shown). Sera from mice (n ϭ 3) immunized twice with KUNgag VLPs showed no significant neutralizing activity, as the VLP titer was 6.3 ϫ 10 5 Ϯ 1.3 ϫ 10 5 IU/ml.
Induction of HIV-1 Gag-specific CD8
؉ T-cell responses.
HIV-1 Gag protein contains a H-2
d -restricted CD8 ϩ T-cell epitope, AMQMLKETI (AMQ), which was used as a peptide to detect Gag-specific CD8 ϩ T-cell responses in immunized BALB/c mice using the IFN-␥ ELISPOT assay. BALB/c mice were immunized once or twice with rrVVgag or KUN replicon vaccines encoding Gag (KUNgag DNA, KUNgagRNA, and KUNgag VLPs). Overall, KUNgag VLPs generated higher CD8 ϩ T-cell responses than KUNgag RNA did, which gave higher responses than KUNgag DNA, with responses from the latter two modalities broadly comparable to that of rVVgag (Fig. 5A ). However, a single immunization with KUNgag VLPs induced a 4.5-fold-greater response than one immunization with rVVgag (KUNgag VLP versus rVVgag, P ϭ 0.012) (Fig.  5A) .
Mice immunized twice with KUNgagRNA, KUNgag VLPs, and rVVgag were also assayed for the induction of cytotoxic T-cell responses by 51 Cr release assay (Fig. 5B ). Significant cytotoxic activity specific for the AMQ epitope was observed (Fig. 5B) . The response induced by immunization with KUNgag VLPs was comparable to that observed in mice immunized with rVVgag.
These data illustrate that KUN replicon-based vaccines can efficiently induce Gag-specific CD8 ϩ T cells, generating responses greater or similar in magnitude to those induced by recombinant vaccinia virus.
KUNgag RNA or KUNgag VLP immunization protects mice from experimental viral challenge. To determine whether the 
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T-cell responses induced by immunization with KUNgag replicon vectors can protect against viral challenge, groups of mice were vaccinated twice with KUNgag VLP or a control VLP not encoding Gag. The mice were then challenged with either rVVgag or a control rVV not encoding Gag (rVVcont). Mice immunized with KUNgag VLPs showed an average reduction of ϳ30-fold (P ϭ 0.0003) in rVVgag titers compared to mice immunized with a control VLP (Fig. 6, top graph) . In a parallel experiment, the mice immunized with KUNgag VLP or control VLPs were challenged with rVVcont, and no significant difference in ovary rVVcont titers was observed (P ϭ 0.9) (Fig. 6 , bottom graph). This illustrates that Gag-specific immunity was responsible for the KUNgag VLP-mediated reduction in rVVgag titers. The rVV titers in naive animals were not significantly different from those of control VLP-immunized animals in both experiments (data not shown). In a separate experiment, two immunizations with 30 g of KUNgag RNA also resulted in a ϳ95% reduction in ovary rVVgag titers (P ϭ 0.01) (data not shown).
Long-term CD8 ؉ T-cell responses elicited by KUN replicon VLP vaccines. To analyze the long-term CD8
ϩ T-cell immunity induced by KUN VLP vaccines, mice were immunized with a single inoculation of KUNgag VLPs and the AMQ-specific responses were analyzed by an ELISPOT assay after 2 weeks and after 6 months. The responses at 6 months were not significantly different from those seen at 2 weeks (P ϭ 0.75) (Fig.  7A) , illustrating the induction of long-lasting CD8 ϩ T-cell responses by KUNgag VLP immunization. A similar long-term maintenance of epitope-specific CD8 ϩ T cells capable of secreting IFN-␥ was observed after immunization with a KUN VLP encoding the murine polyepitope (KUNmptVLP), a vaccine encoding four H-2 d -restricted CD8 ϩ T-cell epitopes. We have previously published the responses to these four epitopes 2 to 3 weeks after immunization with KUNmptVLP (3), and we now show that after 6 months these responses have not significantly diminished (Fig. 7B) , illustrating that long-term maintenance of CD8 ϩ T-cell responses is not restricted to AMQ-specific CD8 ϩ T cells. Furthermore, when mice, which had been immunized with KUNmptVLP 10 months previously, were challenged with a recombinant vaccinia virus encoding the same four epitopes, substantial protection was still apparent (Fig. 7C) . KUNmptVLP-immunized mice showed an average reduction of ϳ100-fold in ovary virus titers from that of mock-immunized control mice (P ϭ 0.015).
DISCUSSION
We describe here the generation of KUN replicon vaccine vectors carrying the complete HIV-1 gag gene and show that they were able to produce secreted gag particles in vitro. Mice immunized with KUNgag DNA, RNA, or VLPs induced significant Gag-specific CD8 ϩ T-cell responses, with one immunization of KUNgag VLP inducing 4.5-fold-more CD8 ϩ T cells than those induced after immunization with rVVgag. KUNgag VLP and RNA immunization also mediated substantial protection of mice against challenge with rVVgag. Importantly, KUN VLP vaccines were able to induce enduring CD8 ϩ T cells capable of secreting IFN-␥ and mediating protection against vaccinia virus challenge 6 to 10 months postimmunization. These results significantly extend our previous data obtained with murine polyepitope (3) and demonstrate the utility of KUN-based vectors for HIV vaccine design.
The ability to induce HIV Gag-specific immune responses effectively appears to depend on the vector's ability to produce Gag protein in the form of secreted, self-assembled gag particles (31) . The assembly of secreted gag particles requires expression of Gag with the native amino-terminal glycine residue (12) . To achieve this, the HIV-1 gag gene was inserted into the KUN replicon vector downstream of the mouse ubiquitin gene (Fig. 1) . Cleavage by cellular proteases at the carboxy terminus of ubiquitin allows the release of Gag with native amino-terminal glycine residue. In order to release the Gag protein from the remaining Gag-KUN polyprotein, the foot-and-mouse disease virus 2A autoprotease sequence was inserted at the C terminus of Gag (Fig. 1) . The results of EM (Fig. 3 ) and of RIPA (Fig. 2A) demonstrated that the Gag protein produced from the KUN replicon RNA vector was correctly processed and assembled into secreted gag particles. Quantitative analysis of Gag expression, using a commercial anti-p24 ELISA kit, in cells transfected with KUNgag RNA showed a high level of total Gag expression of approximately 600 ng per 10 6 initially transfected cells by 60 h posttransfection, with at least onethird of the protein being secreted into the culture fluid (Fig. 2B) . These very high yields compared to other systems (14, 27, 31) are
gag antibody levels in mice after immunization with KUNgag VLPs and rVVgag. Mice were immunized twice with 10 6 IU of KUNgag VLPs or control KUN VLPs or once with 2 ϫ 10 7 PFU of rVVgag. Two to three weeks after the last immunization, mouse sera were analyzed for anti-pr55 gag antibodies using an ELISA against purified recombinant pr55 gag protein, as described in Materials and Methods. Optical density at 450 nm (OD 450 ) is shown on the y axis, while the dilution of the serum sample is shown on the x axis.
likely to reflect the ability of the transfected cells to divide within the 60-h incubation period, with daughter cells retaining replicating KUNgag RNA and Gag protein production (41) .
A major problem for efficient expression of native HIV structural genes when plasmid DNA-based expression vectors are used is the presence of multiple inhibitory sequences, which are responsible for poor transport of mRNAs from the nucleus to the cytoplasm (32, 35) . The advantage of cytoplasmic virus-based vectors like KUN is that they do not require modification of HIV inhibitory sequences to facilitate Gag, Gag-Pol, and Env protein expression. This also appears to be true for KUNgag DNA, since HIV Gag was efficiently expressed by KUNgag DNA transfected cells, as judged by CD8 ϩ T-cell induction (Fig. 5A) . Only a few KUNgag replicon RNA molecules probably need to escape from the nucleus into the cytoplasm to establish a replicating pool of replicon RNA capable of efficient protein production. HIV-1 Gag has been used as the immunogen in a number of murine studies evaluating different vaccine vectors (5, 13, 27, 30, 33, 39) . For instance, three DNA immunizations that targeted Gag to the secretory pathway (pSc-Gag) followed by a rVVgag booster immunization was reported to induce 50 AMQ-specific IFN-␥ spots/10 6 splenocytes at the peak of the CD8 ϩ T-cell response on day 5 (31), whereas more than 150 AMQ-specific IFN-␥ spots/10 6 splenocytes were seen after 3 weeks following a single immunization with KUNgag VLP (Fig.  5) . After two immunizations with KUNgag VLPs, a challenge with rVVgag resulted in an average reduction of ϳ30-fold in ovary vaccinia virus titers, a protective activity known to be mediated by Gag-specific CD4 and CD8 ϩ T cells (24) . These results are broadly comparable with related studies measuring protection against rVVgag in mice (31, 33, 39). However, comparisons are complicated by the use of (i) different schedules and routes of immunization, (ii) vaccinia viruses with different virulence characteristics, and (iii) different routes of vaccinia virus challenge (31, 33, 39) .
Two immunizations with KUNgag VLPs induced antibody responses to the replicon-encoded Gag protein with end point titers of approximately 1/10,000, similar to those reported for mice immunized with 10 g of p55 gag protein emulsified in the highly effective MF59 oil-in-water adjuvant (30) . In contrast, the induction of neutralizing anti-KUN VLP vector antibodies by KUN VLP vaccines appeared to be inefficient as evidenced by (i) the ability to effectively boost KUNgag VLP-induced responses with KUNgag VLPs (Fig. 5 and 6 ), and (ii) the failure to detect significant levels of neutralizing antibodies to the KUN envelope protein after two immunizations with KUNgag VLPs (see Results). The latter is certainly not the case after two immunizations with recombinant vaccinia viruses (4) . Although the majority of the world's populations have no anti-KUN neutralizing antibodies, cross-reactive flavivirus-specific CD8 ϩ T cells recognizing nonstructural proteins may be widespread (38) . However, current evidence suggests that such preexisting anti-vector CD8 ϩ T-cell responses need to be extremely high before they effectively interfere with a vaccine vector's ability to raise CD8 ϩ T-cell responses specific for the vaccine antigen (37) .
Perhaps the most impressive outcome of KUN VLP immunization is the maintenance for 6 to 10 months of CD8 ϩ T cells that are capable of immediate IFN-␥ secretion and of mediating protection within the 4 days of the rVV challenge assay (Fig. 7) . Such long-term maintenance of effector CD8 ϩ T cells capable of immediate protective activities may emerge as an important feature of effective vaccination against HIV, since the postchallenge generation of new effectors from a vaccineinduced memory CD8
ϩ T-cell pool may simply be too slow to 
